<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909400</url>
  </required_header>
  <id_info>
    <org_study_id>KH176-201</org_study_id>
    <nct_id>NCT02909400</nct_id>
  </id_info>
  <brief_title>The KHENERGY Study</brief_title>
  <acronym>KHENERGY</acronym>
  <official_title>An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A&gt;G Mutation and Clinical Signs of Mitochondrial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khondrion BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud Center for Mitochondrial Medicine (RCMM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Khondrion BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitochondrial Diseases are rare, progressive, multi-system, often-early fatal disorders
      affecting both children and adults. KH176 is a novel chemical entity currently under
      development for the treatment of inherited mitochondrial diseases, including MELAS
      (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), MIDD
      (Maternally Inherited Diabetes and Deafness), Leigh's Disease and LHON (Leber's Hereditary
      Optic Neuropathy). The current Proof of Concept study aims to explore the effects of
      treatment with KH176 for 4 weeks on clinical signs and symptoms and biomarkers of
      mitochondrial disease and to evaluate the safety and pharmacokinetics of KH176 in patients
      with m.3242A&gt;G related mitochondrial disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be a double blind, randomized, placebo-controlled, single-centre, two-way
      cross-over trial. Twenty patients, with a confirmed mitochondrial DNA tRNALeu(UUR) m.3243A&gt;G
      mutation and with clinical signs of mitochondrial disease, will be randomized over 2 groups
      (active or placebo first). After a screening period and a training session, each group will
      have 2 dosing periods of 28 days, with a washout period of at least 28 days in between. On
      these occasions, patients will receive 100 mg KH176 twice daily (treatment A) or a matching
      placebo (treatment B) twice daily for 28 days.

      Clinical assessments will be performed once in a training session prior to baseline, at
      baseline and in week 4 post dosing during each treatment phase (A and B). Testing conditions
      and circumstances, with respect to timing of the assessments, hospitalization and meals, will
      be standardized for each assessement period. Furthermore, assessments of biomarkers for
      mitochondrial functioning, pharmacokinetics and specific safety assessments will be performed
      weekly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Movement disorders</measure>
    <time_frame>one month</time_frame>
    <description>Rater assessed change from baseline of motoric abnormalities and movement characteristics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NMDAS</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline of the Newcastle Mitochondrial Disease Activity Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometric parameters (FVC,FEV1, PEF)</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline in spirometric parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometric parameters (MIP, MEP)</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline in spirometric parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sit to Stand Test (30 seconds)</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of the maximum number of sit-standings in 30 seconds time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Dynamometry</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of the maximum grip strenght</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-min chewing test</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment in rate of mastication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-min chewing test</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of pain and tiredness (VAS) during a 6-min chewing test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-MWT</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of the Distance during a 6-min Walk Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAND-SF36 score</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline in the RAND-SF36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAD and BDI</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline in the Hospital Anxiety and Depression Scale (HAD), supplemented with a Beck Depression Index (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDI</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline in the Beck Depression Index (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIS</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline in the Checklist Individual Strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAP</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of alertness and mental flexibility during a Test of Attentional Performance (TAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goal Attainment Scale</measure>
    <time_frame>one month</time_frame>
    <description>Assessment of pre-defined goal attainment during each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Registration of Motor Activity and Sleeping pattern</measure>
    <time_frame>one month</time_frame>
    <description>During each treatment period a continuous registration of Motor Activity and Sleeping pattern by accelerometer, assessing sleep quality, quantity and overall motor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>one month</time_frame>
    <description>Change from Baseline assessment of vital signs (heart rate, blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>one month</time_frame>
    <description>Change from Baseline assessment of ECG-intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory</measure>
    <time_frame>one month</time_frame>
    <description>Change from Baseline assessment of Clinical Laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KH176 and metabolites</measure>
    <time_frame>one month</time_frame>
    <description>Attainment of steady state and total exposure (AUC) at steady state conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KH176 and metabolites</measure>
    <time_frame>one month</time_frame>
    <description>Attainment of steady state and maximal concentrations (Cmax) at steady state conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of the ratio of oxidized/reduced glutathione in blood samples (GSH/GSSG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood biomarker FGF21</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of FGF21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood biomarker GDF15</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of GDF15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood biomarker PRDX1</measure>
    <time_frame>one month</time_frame>
    <description>Change from baseline assessment of PRDX1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Mitochondrial Diseases</condition>
  <condition>Mitochondrial Myopathies</condition>
  <condition>Mitochondrial Encephalomyopathies</condition>
  <condition>MELAS</condition>
  <condition>MIDD</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of 100 mg KH176 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of matching placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KH176</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females aged 18 years or older at screening

          2. Ability and willingness to sign the Informed Consent Form prior to screening
             evaluations.

          3. Confirmed mitochondrial DNA tRNALeu(UUR) m.3243A&gt;G mutation

          4. Heteroplasmy level as measured in urine â‰¥ 20 %.

          5. Body Mass Index (BMI) 18.0-30.0 kg/m2 (extremes included) at screening

          6. Clinical evidence of mitochondrial disease, positive NMDAS score (including but not
             limited to MELAS, MIDD and mixed types). CPEO patients with signs restricted to the
             eye only are not considered eligible.

          7. Disease appropriate physical and mental health as established by medical history,
             physical examination, electrocardiogram (ECG) and vital signs recording, and results
             of biochemistry, hematology and urinalysis testing within 3 weeks prior to the first
             dose as judged by the Investigator.

          8. Appropriate cardiac functioning as assessed by medical history, ECG and Echo,
             evaluated by a cardiologist.

          9. Able to comply with the study requirements, including exercise testing and swallowing
             study medication

         10. Willingness to use adequate contraceptive methods (male and female) and negative urine
             pregnancy test (females) at screening and first baseline assessment.

         11. Able and willing to refrain from the use of (multi)vitamins, co-enzyme Q10, Vitamine
             E, riboflavin, and anti-oxidant supplements (and idebenone/EPI-743), as well as any
             medication negatively influencing mitochondrial functioning (including but not limited
             to valproic acid, glitazones, statins, anti-virals, amiodarone, and NSAID's) as well
             as any strong Cytochrome P450 inhibitors (all 'conazoles-anti-fungals', HIV
             antivirals, grapefruit) and strong Cytochrome P450 inducers (a.o. carbamazepine,
             phenobarbital, phenytoin, rifampicine, St Johns wort, pioglitazone, troglitazone) as
             well as any medication known to affect cardiac repolarization (all anti-psychotics,
             several anti-depressants: nor/amytriptilline, fluoxetine, anti-emetics: domperidone
             (motilium) granisetron, ondansetron).

        Exclusion Criteria:

          1. Motoric abnormalities other than related to the mitochondrial disease interfering with
             the outcome parameters.

          2. CPEO patients with clinical signs and symptoms restricted to the eye only

          3. Heteroplasmy level as measured in urine &lt; 20%

          4. Poor nutritional state as judged by the investigator

          5. Body Mass Index (BMI) not within 18.0-30.0 kg/m2 at screening.

          6. History of cancer

          7. Surgery or active illness of gastro-intestinal tract that might interfere with
             absorption.

          8. Participation in a trial of an investigational product in the preceding 3 months prior
             to the first dose or during this trial.

          9. Positive drug, alcohol or cotinine test at screening and/or admission (Day 1 of the
             first dosing period).

         10. Clinically relevant abnormal laboratory, ECG recordings, cardiac echo (within 1 year
             prior to screening), vital signs or physical or mental findings at screening as judged
             by the Investigator.

         11. Clinically relevant abnormal ECG or cardiac functioning as judged by a cardiologist.

         12. ECG: QTc &gt; 450 ms, abnormal T-wave

         13. Symptomatic heart failure or signs of ischemic heart disease

         14. Left Ventricular Ejection Fraction &lt;45%

         15. History or family history of congenital Long QT syndrome

         16. Increased or decreased potassium (local laboratory normal range)

         17. Inadequate contraception use, pregnancy or breast feeding (females)

         18. Clinically significant presence or history of allergy as judged by the Investigator.

         19. History of hypersensitivity or idiosyncrasy to any of the components of the
             investigational drug.

         20. Within 4 weeks prior to dosing, the use of:

               -  (multi)vitamins, co-enzyme Q10, Vitamine E, riboflavin, and anti-oxidant
                  supplements (and idebenone/EPI-743),

               -  as well as any medication negatively influencing mitochondrial functioning
                  (including but not limited to valproic acid, glitazones, statins, anti-virals,
                  amiodarone, and NSAID's)

               -  as well as any strong Cytochrome P450 inhibitors (all 'conazoles-anti-fungals',
                  HIV antivirals, grapefruit)

               -  and strong Cytochrome P450 inducers (a.o. carbamazepine, phenobarbital,
                  phenytoin, rifampicin, St Johns wort, pioglitazone, troglitazone)

               -  as well as any medication known to affect cardiac repolarization (all
                  anti-psychotics, several anti-depressants: nor/amitriptyline, fluoxetine,
                  anti-emetics: domperidone (motilium) granisetron, ondansetron)

               -  as well as any medication metabolized by Cytochrome P450 with a narrow
                  therapeutical width. (for reference: drug interaction table of Indiana University
                  http://medicine.iupui.edu/clinpharm/ddis/clinical-table/)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitochondrial</keyword>
  <keyword>oxidative phosphorylation (oxphos)</keyword>
  <keyword>MELAS</keyword>
  <keyword>MIDD</keyword>
  <keyword>KH176</keyword>
  <keyword>Proof of Concept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>Mitochondrial Myopathies</mesh_term>
    <mesh_term>Mitochondrial Encephalomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

